ImmunityBio (IBRX) announced new findings from the Phase 2 QUILT-3.055 study, presented at the IASLC 2025 World Conference on Lung Cancer. The study demonstrated that ANKTIVA reverses lymphopenia in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback